Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06169540 · ClinicalTrials.gov registry record

Salivary Extracellular Vesicle Associated lncRNAs in Heart Failure (SEAL-HF)

A clinical trial of Control and CHF, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
90
Enrollment target
1
Study location

NCT06169540 is a study of Control and CHF that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 90 participants, below the 181-participant average among 5 other Control trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06169540, a study of Control and CHF, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
90 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the relationship between the levels of Ribonucleic acid (RNA) circulating molecules, including ones in extracellular vesicles from different organs in the blood and in the saliva of patients with Acute Decompensated Heart Failure (ADHF) and Chronic Heart Failure (CHF) to see if a new, non-invasive diagnostic test can be developed for heart failure exacerbation.

Conditions Studied

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2023-04-19
Est. Completion 2027-12-31

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT06169540

The ClinicalTrials.gov registry entry for NCT06169540 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 5 other Control trials with a reported enrollment target (50% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Control appearing as the primary indexed condition, and to 0 interventions.

NCT06169540 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06169540 about?

NCT06169540 is a clinical study titled "Salivary Extracellular Vesicle Associated lncRNAs in Heart Failure (SEAL-HF)". The purpose of this study is to determine the relationship between the levels of Ribonucleic acid (RNA) circulating molecules, including ones in extracellular vesicles from different organs in the blood and in the saliva of patients with Acute Decompensated Heart Failure (ADHF) and Chronic Heart Fai...

What is the current status of trial NCT06169540?

This trial is currently recruiting. The enrollment target is 90 participants. The study started on 2023-04-19. Estimated completion is 2027-12-31.

What conditions does trial NCT06169540 study?

This clinical trial studies the following conditions: Control, CHF, ADHF.

Who is sponsoring clinical trial NCT06169540?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06169540 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Control

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.